My Top 3 Stocks to Buy in May

The article argues TransMedics is attractive after a Q1 2026 EPS miss of $0.30 vs. $0.61 consensus, while revenue still rose 21% year over year. Rhythm has multiple catalysts, including FDA approval on March 19, 2026, European authorization on May 1, and a Japanese regulatory review expected in 2H 2026. Enbridge offers stability with a 5.2% dividend yield, 31 consecutive annual dividend increases, and roughly $50 billion of growth opportunities through 2030.

Analysis

The market is treating TMDX like a one-quarter story, but the real setup is a capacity-and-penetration thesis: if management can keep logistics execution from outrunning gross margin, the selloff creates asymmetry because the next leg of growth can come from expanding organ categories and geographies rather than just more utilization in the current franchise. The key second-order effect is that a kidney launch would materially widen the addressable pool and could force transplant centers to rethink procurement workflows around a more integrated, premium service model—raising switching costs for rivals that only sell hardware or only logistics.

RYTM’s upside is less about near-term pricing and more about regulatory de-risking converting a rare-disease label into a multi-region commercialization engine. The market may still be underappreciating the option value of label expansion across multiple geographies because each approval compounds physician familiarity and payer leverage; that tends to compress the timeline to meaningful revenue inflection faster than consensus models expect. The main risk is that PWS data becomes a classic “good but not broad enough” catalyst, where enthusiasm spikes on headline results but fades if durability or real-world adherence is messy.

ENB is the cleanest expression of the theme that infrastructure cash flows are worth more when macro volatility stays elevated. Its dividend profile and utility-like earnings should continue to attract capital from investors rotating out of lower-quality yield names, especially if rates remain rangebound or drift lower; that creates a duration-like bid for the shares. The catch is that ENB is more of a slow compounding trade than a rerating story, so upside depends on execution against the growth backlog rather than multiple expansion.

The contrarian read is that the strongest opportunities are in the names with the most visible near-term disappointment, not the obvious quality compounder. TMDX and RYTM can both rerate sharply if upcoming prints or trial data remove a single overhang, while ENB likely grinds rather than surges. In other words, the selloff in TMDX may be overdone relative to its long-dated TAM expansion, while RYTM is the higher-beta catalyst basket; ENB is the capital preservation anchor, not the alpha engine.

Key Decisions for Investors

• Long TMDX on weakness over the next 1-3 weeks; use the post-earnings reset to build a position with a 6-12 month horizon. Risk/reward favors a 2-3x upside scenario if European rollout and kidney-program milestones re-rate the story, but cut if margins keep deteriorating for two consecutive quarters.
• Buy RYTM ahead of the next 4-8 weeks of catalyst flow, but size smaller than TMDX because event risk is binary. Best entry is on any fade after approval-driven momentum; upside is a multiple expansion if PWS data supports duration and commercial uptake.
• Use ENB as a defensive long in a volatile tape, preferably as a 3-6 month income-plus trade. The risk/reward is lower beta and lower drawdown, with dividend support offsetting limited rerating potential.
• Pair trade: long TMDX / short a broad healthcare equipment basket over 3-6 months. Thesis: idiosyncratic execution and TAM expansion should outperform slower-growth medtech peers if margins stabilize.
• For higher-risk accounts, consider RYTM call spread exposure into the next trial readout rather than common stock. This captures catalyst upside while defining downside if the market fades the event.